Stock Market Reviews

ACRS (Aclaris Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ACRS (Aclaris Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
  Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Oct 21, 2025 - $ACRS
• Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  Oct 12, 2025 - $ACRS
• Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
  WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company’s progress in addressing therapeutic gaps in immuno-inflammatory markets. To register, please click here. The event will feature presentat
  Sep 30, 2025 - $ACRS
• Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight
  Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is among the best fundamentally strong penny stocks to buy right now. According to the recent Form 13F filing with the SEC, Acadian Asset Management LLC expanded its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.9% in the first quarter. With the purchase of 451,044 shares, the investment manager now owns […]
  Sep 21, 2025 - $ACRS
• With 56% institutional ownership, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a favorite amongst the big guns
  Key Insights Institutions' substantial holdings in Aclaris Therapeutics implies that they have significant influence...
  Sep 21, 2025 - $ACRS
• Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
  Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Sep 18, 2025 - $ACRS
• Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
  - Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2
  Sep 9, 2025 - $ACRS
• This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year
  From what we can see, insiders were net buyers in Aclaris Therapeutics, Inc.'s ( NASDAQ:ACRS ) during the past 12...
  Aug 31, 2025 - $ACRS
• Aclaris Therapeutics to Participate in Two September Healthcare Conferences
  WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside cha
  Aug 27, 2025 - $ACRS
• Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138
  Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5. On July 29, Aclaris Therapeutics announced positive top-line results from its Phase 2a clinical trial of ATI-2138. This is a potent and selective oral inhibitor of interleukin-2-inducible T cell kinase/ITK and Janus kinase 3/JAK3, which are both enzymes involved in immune […]
  Aug 18, 2025 - $ACRS